Latest News - Earnings & Financials

Friday, December 15, 2017 | Earnings & Financials, Presbia

Presbia Announces Board and Management Changes and Financing Proposal to Operate Through to the End of 2018

Presbia announced that it has reordered its operational priorities to focus its resources on FDA approval as well as ongoing clinical and commercial efforts in Germany and South Korea. These actions r…

Read the full story

Thursday, December 14, 2017 | Earnings & Financials

Teva's New CEO to Cut 25% of Jobs to Rescue Ailing Drugmaker

Teva Pharmaceutical Industries announced some of the most sweeping job cuts in the drug industry, eliminating 14,000 positions globally as new Chief Executive Officer Kare Schultz seeks to stabilize a…

Read the full story

Monday, December 11, 2017 | Earnings & Financials

Teva Considers 10,000 Job Cuts

Teva Pharmaceutical Industries, the debt-ridden Israeli drugmaker, is considering cutting as many as 10,000 jobs as new Chief Executive Officer Kare Schultz seeks to pare costs, according to people wi…

Read the full story

Monday, November 27, 2017 | Earnings & Financials

Teva Pharm Overhauls Structure and Top Management

Teva Pharmaceutical Industries is streamlining its company structure and making sweeping changes to senior management as part of an overhaul it hopes will please investors worried about the company&rs…

Read the full story

Monday, November 20, 2017 | Earnings & Financials

Aston EyeTech Completes £5m Series A Equity Round

Aston EyeTech announced it has completed a £5m Series A funding round. The company will use this new funding to accelerate product development and support the 2018 launch of its new prod…

Read the full story

Tuesday, November 14, 2017 | Earnings & Financials

Q BioMed Announces Funding to Technology Partner Mannin Research to Expand Product Pipeline

Q BioMed' collaborative research partner and licensor, Mannin Research, has received R&D funding from the National Research Council of Canada Industrial Research Assistance Program (…

Read the full story

Thursday, November 09, 2017 | Earnings & Financials

Apellis Pharmaceuticals Announces Pricing of Initial Public Offering

Apellis Pharmaceuticals announced the pricing of its initial public offering of 10,714,000 shares of common stock at a public offering price of $14 per share, for total gross proceeds of approximately…

Read the full story

Wednesday, November 08, 2017 | Earnings & Financials, TearLab Corp.

Nasdaq to Delist TearLab Tomorrow After failing to Meet Listing Requirements

Citing its failure to meeting listing requirements for minimum market cap and stockholders' equity, Nasdaq has notified TearLab that it will delist its shares at the open tomorrow, November 9. S…

Read the full story

Wednesday, November 08, 2017 | Earnings & Financials, Bausch+Lomb, Valeant

Valeant Profit Beats on Bausch & Lomb Strength

Valeant Pharmaceuticals reported a better-than-expected quarterly profit on strength in its Bausch and Lomb eye-care business, and the Canadian drugmaker maintained its full-year adjusted earnings for…

Read the full story

Tuesday, November 07, 2017 | Earnings & Financials, Guardian Health Sciences

Guardion Health Sciences Closes $5 Million Common Equity Financing

Guardion Health Sciences completed a private placement of its common stock on November 3, 2017, raising an aggregate of $5,000,001.05 through the sale of 4,347,827 shares of common stock. Guardion …

Read the full story

Friday, November 03, 2017 | Earnings & Financials, Glaucoma, Nicox

Nicox Highlights Vyzulta Approval, Latest Corporate and Financial Developments, and Upcoming Pipeline Initiatives

Nicox highlighted recent regulatory progress, with the approval in the United States of its partnered product, Vyzulta (latanoprostene bunod ophthalmic solution 0.024%), and provided an overview of th…

Read the full story

Wednesday, November 01, 2017 | Earnings & Financials

Genisphere Raises $7 Million to Advance 3DNA Drug Delivery System

Genisphere announced it has completed a $7 million capital raise to advance its 3DNA nanotechnology platform for targeted drug delivery and to serve other corporate purposes. Genisphere completed the …

Read the full story

Tuesday, October 31, 2017 | Earnings & Financials

LumiThera Closes New Round of Financing to Support Dry AMD Treatment Device

LumiThera, a clinical stage private medical device company creating a non-invasive photobiomodulation (PBM) treatment for ocular disorders and diseases, announced it has completed the Series B round o…

Read the full story

Tuesday, October 24, 2017 | Earnings & Financials, Nicox

Nicox Provides Update on Zerviate and Ophthalmic Pipeline

Nicox SA provided an update on its activities and cash balance as of September 30, 2017. Earlier this month, Nicox entered into two collaborations to explore the potential for sustained-release for…

Read the full story

Wednesday, October 18, 2017 | Earnings & Financials

Gemini Therapeutics Announces $42.5 Million Series A Financing to Develop Precision Therapeutics in Ophthalmology and Rare Genetic Diseases

Gemini Therapeutics, a new precision medicine company focused on genetically-defined dry age-related macular degeneration (AMD) and associated rare genetic diseases, announced that it has completed a …

Read the full story
Load More